8-K: Altria Reports Strong 2025 Adjusted EPS, Guides 2026 Growth

Altria Group, Inc. announced its 2025 fourth-quarter and full-year results, reporting 4.4% adjusted diluted EPS growth for 2025 and providing 2026 guidance of $5.56 to $5.72.

Summary

• Adjusted diluted earnings per share (EPS) grew 4.4% in 2025 to $5.42.
• Returned $8 billion to shareholders in 2025 through dividends and share repurchases.
• Provided 2026 full-year adjusted diluted EPS guidance in a range of $5.56 to $5.72, representing a growth rate of 2.5% to 5.5% from the 2025 base of $5.42.
• Net revenues decreased 2.1% to $5.846 billion in Q4 2025 and 3.1% to $23.279 billion for the full year 2025.
• Reported diluted EPS decreased 63.1% to $0.66 in Q4 2025 and 37.0% to $4.12 for the full year 2025, primarily due to non-cash impairment charges in the e-vapor products segment.
• Adjusted diluted EPS for Q4 2025 was unchanged at $1.30.
• Smokeable products segment domestic cigarette shipment volume decreased 7.9% in Q4 and 10.0% for the full year 2025.
• Oral tobacco products segment domestic shipment volume decreased 6.3% in Q4 and 5.5% for the full year 2025.
• Helix received FDA marketing authorizations for on! PLUS products in mint, wintergreen, and tobacco flavors, each with 6mg and 9mg nicotine strengths.
• The Optimize & Accelerate Initiative is performing in line with original expectations, targeting at least $600 million in cumulative cost savings by the end of 2029, with updated estimated pre-tax charges of approximately $175 million.
• Achieved a debt-to-Consolidated EBITDA ratio of 2.0x at year-end 2025, meeting the target.
• Maintained a total adjusted operating companies income (OCI) margin of 62.4% for 2025, exceeding the goal of at least 60%.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed but generally stable report. While adjusted EPS growth and shareholder returns are positive and guidance is in line with expectations, significant reported EPS declines due to e-vapor impairments and continued volume pressure in core segments present ongoing challenges.

Positives

• Adjusted diluted EPS grew 4.4% in 2025 to $5.42, demonstrating strong financial performance.
• Returned $8 billion to shareholders in 2025 through $7.0 billion in dividends and $1 billion in share repurchases.
• Increased the dividend by 3.9% in 2025, marking the 60th increase in the past 56 years.
• The debt-to-Consolidated EBITDA ratio was 2.0x at year-end 2025, meeting the target.
• The total adjusted OCI margin was 62.4% for 2025, exceeding the goal of at least 60%.
• on! PLUS products received FDA marketing authorizations for mint, wintergreen, and tobacco flavors in 6mg and 9mg nicotine strengths, expanding the smoke-free portfolio.
• The Optimize & Accelerate Initiative is on track to deliver at least $600 million in cumulative cost savings by the end of 2029.
• Maintained an industry-leading share of the U.S. nicotine space in 2025.
• FUMi is competing across 40,000 retail locations in seven international markets.
• Proper Wild achieved broad commercial distribution to over 25,000 stores in 2025, indicating progress in non-nicotine categories.

Negatives

• Net revenues decreased 2.1% in Q4 2025 and 3.1% for the full year 2025, primarily driven by lower net revenues in the smokeable products segment.
• Reported diluted EPS decreased significantly by 63.1% in Q4 2025 and 37.0% for the full year 2025, primarily due to $2.2 billion in non-cash impairment charges of e-vapor reporting unit goodwill and definite-lived intangible assets.
• Smokeable products segment domestic cigarette shipment volume decreased 7.9% in Q4 and 10.0% for the full year 2025, driven by industry decline and growth of illicit e-vapor products.
• Marlboro retail share of the total cigarette category decreased 1.5 share points in Q4 and 1.2 share points for the full year 2025.
• Oral tobacco products segment domestic shipment volume decreased 6.3% in Q4 and 5.5% for the full year 2025, primarily due to retail share losses.
• on! nicotine pouches total U.S. oral tobacco category share decreased 1.0 share point in Q4 2025 and its share of the nicotine pouch category decreased 5.3 share points in Q4.
• Estimated pre-tax charges for the Optimize & Accelerate Initiative increased from a prior estimate of approximately $125 million to approximately $175 million.
• The e-vapor products segment reported a significant operating loss of $(1,259) million in Q4 2025 and $(2,297) million for the full year 2025.
• NJOY ACE is not expected to return to the marketplace in 2026, impacting e-vapor product volumes.

Risks

• Inability to anticipate and respond to changes in adult nicotine consumer preferences and purchase behavior.
• Inability to compete effectively.
• The growth of the e-vapor category, including illicit disposable e-vapor products, which contributes to reductions in domestic cigarette consumption levels and shipment volume.
• The impact of illicit trade in nicotine products and the sale of products designed to avoid the regulatory framework for nicotine products.
• Failure to develop and commercialize innovative products, including nicotine products that may reduce health risks.
• Changes, including in macroeconomic and geopolitical conditions (e.g., inflation and tariffs), that result in shifts in adult nicotine consumer disposable income and purchasing behavior, including choosing lower-priced and discount brands or products, and reductions in shipment volumes.
• Unfavorable outcomes with respect to litigation proceedings or any governmental investigations, including significant monetary and non-monetary remedies and importation bans.
• The risks associated with significant federal, state, and local government actions, including FDA regulatory actions and inaction.
• The risk that regulators, including the FDA, and courts may interpret laws, rules, and regulations applicable to operating companies' products differently.
• Increases in nicotine product-related taxes.
• Failure to complete or manage successfully strategic relationships or transactions, including acquisitions, dispositions, joint ventures, commercial relationships, and investments in third parties, or realize the anticipated benefits of such transactions.
• Significant changes in price, availability, or quality of tobacco, other raw materials, or component parts.
• Reliance on a few significant facilities and a small number of key suppliers, distributors, and distribution chain service providers.
• The risk that the company may be required to write down goodwill and intangible assets, including trademarks and other intellectual property, due to impairment.
• The risks associated with the Optimize & Accelerate Initiative, including risks relating to business continuity, internal control over financial reporting, and the ability to recognize expected efficiencies.
• The risk that the company could decide, or be required, to recall products.
• The various risks related to health epidemics and pandemics.
• Inability to attract and retain a highly skilled workforce due to the decreasing social acceptance of tobacco usage, tobacco control actions, and other factors.
• The risks associated with the various U.S. and foreign laws and regulations to which the company is subject due to international business operations.
• The risks concerning a challenge to tax positions, an increase in the income tax rate, or other changes to federal or state tax laws.
• The risks associated with legal and regulatory requirements related to climate change and other environmental sustainability matters.
• Disruption and uncertainty in the credit and capital markets, including risk of losing access to these markets.
• A downgrade or potential downgrade of credit ratings.
• The impact of heightened focus by investors and other stakeholders on performance relating to corporate responsibility matters.
• The failure of information systems to function as intended, or cyber-attacks or security breaches affecting the company or its key service providers or key suppliers.
• Failure to comply with laws related to personal data protection, privacy, artificial intelligence, and information security.
• The risk that the expected benefits of the investment in ABI may not materialize.
• The risks associated with the investment in Cronos, including legal, regulatory, and reputational risks.

Future Outlook

Altria expects 2026 full-year adjusted diluted EPS to be in the range of $5.56 to $5.72, representing a growth rate of 2.5% to 5.5% from the 2025 base of $5.42. This growth is anticipated to be weighted towards the second half of the year due to increasing cigarette import and export activity. The guidance factors in planned investments for contract manufacturing and innovative products, limited impact from illicit e-vapor enforcement, and the assumption that NJOY ACE will not return to the market in 2026.

Management Comments

• "2025 was a year of continued momentum for Altria, marked by strong financial performance, strategic progress across our smoke-free portfolio, new relationships in support of our long-term growth goals and significant cash returns to shareholders."
• "For the full year, we grew adjusted diluted earnings per share by 4.4% and returned $8 billion to shareholders through dividends and share repurchases combined."
• "We expect to deliver 2026 full-year adjusted diluted EPS in a range of $5.56 to $5.72. This range represents a growth rate of 2.5% to 5.5% from a base of $5.42 in 2025."

Industry Context

StockSavvy.ai notes that the U.S. tobacco industry continues to face significant headwinds from declining cigarette consumption, exacerbated by the "continued growth of illicit e-vapor products and discretionary income pressures on ANCs." The oral nicotine pouch category, while growing overall (up 14% for the six months ended December 31, 2025), saw Altria's on! brand lose market share within this segment, indicating intense competition and the impact of unregulated products. The substantial impairment charges in the e-vapor segment highlight the challenges and volatility in this evolving market, particularly with regulatory uncertainties and the absence of NJOY ACE.

Comparison to Industry Standards

• Altria's debt-to-Consolidated EBITDA ratio of 2.0x at year-end 2025 is in line with its target of approximately 2.0x, indicating sound financial leverage management within the industry.
• The total adjusted OCI margin of 62.4% for 2025 surpasses Altria's goal of at least 60%, demonstrating strong operational efficiency compared to its internal benchmarks.
• The decline in domestic cigarette shipment volume (7.9% in Q4 and 10.0% for full year 2025) is attributed to the "industry's decline rate," suggesting Altria's performance is largely reflective of broader market trends in combustible tobacco, which are impacted by illicit e-vapor products and consumer discretionary income pressures.
• The U.S. nicotine pouch category grew by an estimated 14% for the six months ended December 31, 2025, indicating a robust growth segment. However, Altria's on! brand saw its share of this category decrease by 5.3 share points in Q4 and 3.4 share points for the full year, suggesting it is losing ground to competitors within this rapidly expanding market.

Management Changes

Corporate Governance

Legal Proceedings

• International Trade Commission's (ITC) exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the United States, resulting in $51 million in related expenses for full-year 2025.
• Pre-tax charges of $58 million for tobacco and health and certain other litigation items and related interest costs for full-year 2025 (compared to $101 million for full-year 2024).

Related Party Transactions

• Equity investments in Anheuser-Busch InBev SA/NV (ABI) and Cronos Group Inc. (Cronos), with associated special items and income/losses from investments.
• A pre-tax gain of $2.7 billion in 2024 upon the assignment of the IQOS Tobacco Heating System commercialization rights to Philip Morris International Inc.

Stakeholder Impact

• Shareholders: Received $8 billion in cash returns (dividends and share repurchases) in 2025. Adjusted EPS growth and 2026 guidance are in line with long-term targets, but reported EPS was significantly impacted by impairments.
• Employees: The Optimize & Accelerate Initiative involves "modernizing ways of working" and incurred "employee separation costs" (mentioned in 2024 charges), indicating potential workforce adjustments.
• Customers (Adult Nicotine Consumers): Continued focus on building a portfolio of FDA-authorized smoke-free products and exploring non-nicotine categories. However, illicit e-vapor products and discretionary income pressures are impacting purchasing behavior.
• Creditors: Debt-to-Consolidated EBITDA ratio of 2.0x meets the target, indicating stable creditworthiness.

Next Steps

• Continue to reassess smoke-free goals and provide updated goals when there is more clarity on the legitimate e-vapor market evolution.
• Continue testing internallyand partner-developed concepts and products to garner consumer and marketplace insights for non-nicotine strategies.
• Salvatore Mancuso to become Altria's Chief Executive Officer, effective May 14, 2026.
• The $2 billion share repurchase program, with $1 billion remaining, expires on December 31, 2026.

Key Dates

Recommendation

Altria's 2025 adjusted EPS growth and 2026 guidance are in line with its long-term targets, demonstrating consistent performance in its core business and commitment to shareholder returns through dividends and buybacks. However, the significant non-cash impairment charges in the e-vapor segment and continued declines in smokeable product volumes, exacerbated by illicit e-vapor competition, highlight ongoing structural challenges. While the company is making strategic progress in smoke-free and non-nicotine areas, these are still developing. The stock offers a strong dividend yield but faces headwinds that limit significant upside potential in the near term, warranting a "hold" position for investors seeking income and moderate stability.

Keywords

Altria, MO, earnings, financial results, EPS, dividend, share repurchase, smoke-free, oral tobacco, e-vapor, FDA, NJOY, on!, Marlboro, tobacco, nicotine, corporate governance, risk management, 2025 results, 2026 guidance, SEC filing